首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >A Case Series of Young Patients with Completely Reversed Severe Pulmonary Hypertension
【2h】

A Case Series of Young Patients with Completely Reversed Severe Pulmonary Hypertension

机译:完全逆转重度肺动脉高压青年患者的病例系列

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary Arterial Hypertension (PAH) is a progressive symptomatic disorder, which may ultimately lead to death if left untreated. Although majority of PAH cases are idiopathic, pulmonary hypertension resulting due to certain underlying conditions are also observed frequently. In such cases, it becomes essential to identify any potentially treatable or reversible causes for PAH. There have been significant advances in the medical management of PAH and various medicines have been approved by US Food and Drug Administration (FDA) for various stages of PAH. With these therapies, there can be varying degrees of improvement in the pulmonary artery pressures and hemodynamic profile. Therefore, physiologic reversal can and does occur, sometimes to the point of normalization. We hereby present three such cases of severe PAH in patients below 50 years of age due to various aetiologies like left heart disease, isolated unilateral absence of right pulmonary artery with hypoplastic right lung and factor V Leiden mutation associated pulmonary thromboembolism, all of whose pulmonary artery pressures are completely normalised with adequate treatment of the underlying disease and with optimised medications for PAH, ultimately leading to tapering and stoppage of PAH medications.
机译:肺动脉高压(PAH)是一种进行性症状性疾病,如果不及时治疗,可能最终导致死亡。尽管大多数PAH病例是特发性的,但也经常观察到由于某些潜在疾病导致的肺动脉高压。在这种情况下,必须确定任何可能治疗或可逆的PAH原因。 PAH的医学管理取得了重大进展,美国食品药品监督管理局(FDA)批准了各种药物用于PAH的各个阶段。通过这些疗法,肺动脉压力和血液动力学特征可以有不同程度的改善。因此,生理逆转可以而且确实发生,有时达到正常化的程度。在此,我们提出3例在50岁以下的患者中因各种病因而发生严重PAH的原因,如左心脏病,孤立的单侧右肺动脉缺失,右肺发育不良和V Leiden突变与肺血栓栓塞有关,所有这些患者的肺动脉通过适当治疗潜在疾病和优化PAH药物,可以使血压完全正常化,最终导致PAH药物逐渐减少和停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号